Josephine Hai

Josephine Hai is a Principal Scientist at Bristol Myers Squibb since March 2021, focusing on preclinical and translational biomarker studies for oncology. Prior experience includes a role as Senior Scientist at Merck, where Josephine led pharmacology efforts for immuno-oncology and collaborated on preclinical data generation, resulting in multiple publications. At Dana-Farber Cancer Institute, Josephine held dual roles as Staff Scientist I and HMS Postdoctoral Fellow, leading research on anti-PD-1 therapies for lung cancer, contributing to multiple high-impact publications. Earlier career stages include a postdoctoral fellowship and doctoral studies at the Princess Margaret Cancer Centre and the University of Toronto, respectively, with a strong focus on lung cancer biomarkers and targeted therapies, resulting in several co-authored publications in prestigious journals. Josephine holds a PhD in Medical Biophysics from the University of Toronto and has completed a postdoctoral fellowship in Medical Oncology at Harvard Medical School.